NEVVI Medicare utilization intelligence

← back

WILDER, DIANEM.D. NPI 1619959525 Clinician

Medical Oncology · LITTLE ROCK, AR

Specialty Medical Oncology — from billed Medicare claims
Trained UNIVERSITY OF TEXAS MEDICAL SCHOOL AT SAN ANTONIO — medical school, self-reported to CMS
In practice about 30 years since medical school (class of 1996, self-reported to CMS)
Location LITTLE ROCK, AR · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 94 codes billed · 160,234 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-03

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9263 Injection, oxaliplatin, 0.5 mg
J9025 Injection, azacitidine, 1 mg
J9299 Injection, nivolumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J0897 Injection, denosumab, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J9267 Injection, paclitaxel, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0461 Injection, atropine sulfate, 0.01 mg
Q5114 Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
36415 Insertion of needle into vein for collection of blood sample
J0894 Injection, decitabine, 1 mg
J1434 Injection, fosaprepitant (focinvez), 1 mg
J9041 Injection, bortezomib, 0.1 mg
J2469 Injection, palonosetron hcl, 25 mcg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
J1626 Injection, granisetron hydrochloride, 100 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96375 Injection of additional new drug or substance into vein
J2919 Injection, methylprednisolone sodium succinate, 5 mg
82378 Carcinoembryonic antigen (cea) protein level
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
96413 Administration of chemotherapy into vein, 1 hour or less
J0640 Injection, leucovorin calcium, per 50 mg
J3480 Injection, potassium chloride, per 2 meq
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
96372 Injection of drug or substance under skin or into muscle
J9190 Injection, fluorouracil, 500 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J9045 Injection, carboplatin, 50 mg
J3475 Injection, magnesium sulfate, per 500 mg
J1200 Injection, diphenhydramine hcl, up to 50 mg
96415 Administration of chemotherapy into vein, each additional hour
82728 Ferritin (blood protein) level
J3490 Unclassified drugs
83540 Iron level
83550 Iron binding capacity
83735 Magnesium level
82306 Vitamin d-3 level
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96417 Administration of additional new drug or substance into vein, 1 hour or less
96361 Infusion into a vein for hydration, each additional hour
82784 Gammaglobulin (immune system protein) measurement
J3489 Injection, zoledronic acid, 1 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J7030 Infusion, normal saline solution , 1000 cc
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
82533 Cortisol (hormone) measurement, total
82607 Cyanocobalamin (vitamin b-12) level
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96523 Irrigation of implanted venous access drug delivery device
96360 Infusion into a vein for hydration, 31-60 minutes
82746 Folic acid level, serum
84443 Blood test, thyroid stimulating hormone (tsh)
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
84439 Thyroxine (thyroid chemical), free
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
81003 Automated urinalysis test
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96411 Administration of additional new drug or substance into vein using push technique
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96377 Application of on-body injector for under skin injection
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99443 Telephone medical discussion with physician, 21-30 minutes
82565 Blood creatinine level
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96374 Injection of drug or substance into vein
84165 Protein measurement, serum
83883 Nephelometry, test method using light
99195 Drawing of blood for a medical problem
99442 Telephone medical discussion with physician, 11-20 minutes
J1940 Injection, furosemide, up to 20 mg
84153 Psa (prostate specific antigen) measurement, total
86334 Immunologic analysis technique on serum (immunofixation)
G0008 Administration of influenza virus vaccine
83615 Lactate dehydrogenase (enzyme) level
90661 Influenza vaccine, trivalent derived from cell cultures
93702 Measurement of lymphedema extracellular fluid
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96409 Administration of chemotherapy into vein using push technique
90480 Admn sarscov2 vacc 1 dose
91320 Sarscv2 vac 30mcg trs-suc im

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.